Navigation Links
New model for probing antidepressant actions
Date:2/18/2011

The most widely prescribed antidepressants medicines such as Prozac, Lexapro and Paxil work by blocking the serotonin transporter, a brain protein that normally clears away the mood-regulating chemical serotonin. Or so the current thinking goes.

That theory about how selective serotonin reuptake inhibitors (SSRIs) work can now be put to the test with a new mouse model developed by neuroscientists at Vanderbilt University.

These mice, described in the online edition of the Proceedings of the National Academy of Sciences (PNAS), express a serotonin transporter that has been genetically altered so that it does not respond to many SSRIs or cocaine.

In addition to testing the theory about how SSRIs work, the new mouse model could lead to the development of entirely new classes of antidepressant medications, said Randy Blakely, Ph.D., Allan D. Bass Professor of Pharmacology and Psychiatry at Vanderbilt and senior author of the PNAS paper.

"Many antidepressants have been shown to target other proteins besides the serotonin transporter and their efficacy in treating depression takes many weeks to develop," Blakely said. "There is likely a lot that we don't know about how these drugs act."

To generate the mouse model, Blakely and colleagues at Vanderbilt and the University of Texas Health Science Center at San Antonio first determined exactly which parts of the serotonin transporter protein interact with SSRIs. They took advantage of the fact that the fruit fly expresses a serotonin transporter that is relatively insensitive to the drugs.

By changing the protein's amino acid building blocks, they converted parts of the human serotonin transporter into its fruit fly equivalent, and in so doing identified the single amino acid required for potent binding to many SSRIs as well as to cocaine.

As predicted, the genetically-modified mice displayed normal serotonin transporter levels, and their transporter exhibited normal activity in clearing serotonin from the synapses between nerve cells. But the mice did not respond to Prozac or Lexapro, indicating that the transporter is indeed the specific target of these medications for blocking serotonin inactivation.

"Interestingly, one SSRI, paroxetine (Paxil), retains its normal powerful action on the transporter, revealing that -- at a molecular level -- different antidepressants interact with the transporter in different ways," Blakely said.

The researchers are now evaluating chronic administration of SSRIs to determine how much the transporter contributes to the more clinically relevant, delayed effects of these drugs, as well as for the side effects experience with antidepressant medications.

Because the serotonin transporter in the mouse also lost cocaine sensitivity, the model also may help researchers determine exactly how cocaine acts in the brain. "Perhaps what started as a hunt for better ways to treat depression may also spill over into a better understanding of addiction," Blakely said.


'/>"/>

Contact: Bill Snyder
bill.snyder@vanderbilt.edu
615-322-4747
Vanderbilt University Medical Center
Source:Eurekalert

Related medicine news :

1. Speedy generic approval may not benefit consumers as much as expected, Rotman model shows
2. Speedy generic approval may not benefit consumers as much as expected, Rotman model shows
3. Weight-Loss Surgery May Remodel Heart
4. UNC researchers developing computer models for pediatric airway problems
5. Breathing easy: LSU biochemists offer first 3-D model of asthma-causing inflammation enzyme
6. Transplanted human placenta-derived stem cells show therapeutic potential in stroke models
7. WSU researchers apply fatigue model to fatal commuter air crash
8. Researchers discover way to halt lung inflammation in animal models
9. Embryonic stem cells help deliver good genes in a model of inherited blood disorder
10. Tutorial addresses multi-cell, multi-scale modeling
11. Model predicts a drugs likelihood of causing birth defects
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/6/2016)... ... 06, 2016 , ... Logically, spring weather, with its moderate humidity and temperatures, ... cold, dry or hot, water on the eye surface can evaporate, creating uncomfortable dry ... air. There’s only one problem, according to radio show and water advocate Sharon Kleyne: ...
(Date:5/6/2016)... ... , ... Canadian author Mark Black is a speaker, author, and life strategy coach ... world … with the help of his publisher Strategic Book Group and its subsidiary ... hospital bed waiting for a miracle: He needed a heart and double-lung transplant. From this ...
(Date:5/6/2016)... , ... May 06, 2016 , ... Yisrayl Hawkins, Pastor and Overseer at The House ... worldwide, what he has found in the Bible about helping to stop cancer. Yisrayl says ... it is his hope that the health and science industries will pay close attention and ...
(Date:5/6/2016)... ... 2016 , ... Kenneth Cochran, DSc, RN, FACHE, President/CEO of ... South announced today that Dr. Robert Menuet, Interventional Cardiologist with Cardiovascular Institute of ... Coronary Atherectomy. , This procedure involves the removal of plaque by ...
(Date:5/5/2016)... Tucson, AZ (PRWEB) , ... May 05, 2016 , ... ... more attention being paid to the impact our aging population has on communities and ... help aging adults plan for and face age-related challenges. , Aging Life Care ...
Breaking Medicine News(10 mins):
(Date:5/5/2016)... Research and Markets has announced the addition ... EU Markets"  report to their offering.  ,     (Logo: http://photos.prnewswire.com/prnh/20160330/349511LOGO ... the current Positron Emission Tomography (PET) scanner and cyclotron install ... includes France , Germany ... and the United Kingdom . Along ...
(Date:5/4/2016)... Holdings (NYSE: CODI ) ("CODI," "we," "our" ... businesses, announced today its consolidated operating results for the ... Quarter 2016 Highlights , Generated Cash Flow Available ... $13.6 million for the first quarter of 2016; ... first quarter of 2016; , Paid a first ...
(Date:5/4/2016)... JERUSALEM , May 4, 2016 ... University of Jerusalem announced today that it had ... BioTheryX, Inc. , developer of novel protein degradation ... the development and commercialization of drug candidates representing first-in-class ... the license were not disclosed. The novel ...
Breaking Medicine Technology: